Swedish startup Ironic Biotech has raised €1M to develop plant-derived proteins that provide bioavailable iron without side effects.

The company's patented iron compounds are cultivated using precision fermentation technology at the University of Lund.

Ironic Biotech's innovation targets the global issue of iron deficiency and anemia, affecting up to a quarter of the world's population.

Their product offers an alternative to traditional iron supplements, which often cause side effects, and to expensive iron infusion therapies.

CEO Dr. Nélida Leiva Eriksson, driven by her own experiences with iron deficiency, aims to aid 2 billion people, focusing on women who are disproportionately affected.

Ironic Biotech plans to introduce their iron-rich proteins into the market by 2025, emphasizing gender equality and social responsibility.